<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864431</url>
  </required_header>
  <id_info>
    <org_study_id>VitDCaOV</org_study_id>
    <nct_id>NCT04864431</nct_id>
  </id_info>
  <brief_title>Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer</brief_title>
  <acronym>VitD</acronym>
  <official_title>The Effect of Vitamin D on Factors Contributing Pre Cachexia and Cachexia, a Study on Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dharmais National Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several ex vivo, in vitro, and observational studies on various type of cancer shown positive&#xD;
      effect of vitamin D. Vitamin D has widely known as immunomodulator property in various&#xD;
      diseases. However, it remains limited studies on immunity and cachexia in cancer,&#xD;
      particularly in ovarian cancer. This study will investigate the effect of vitamin D in immune&#xD;
      response during chemotherapy among epithelial ovarian cancer patients who have a low level of&#xD;
      vitamin D and cachexia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies result from laboratory suggested that vitamin D inhibit cancer cell proliferation and&#xD;
      upregulate apoptosis pathway. Data from observational and ecology studies showed the inverse&#xD;
      relationship between level of vitamin D and cancer risk. Clinical trials on colorectal,&#xD;
      prostate, and breast cancer suggested that vitamin D had positive effect and improved&#xD;
      clinical markers.&#xD;
&#xD;
      Vitamin D may alter immune response through regulation on cytotoxic CD8 T-lymphocyte and&#xD;
      reduce pro inflammatory cytokines. High level of interleukin-6 and other cytokines in cancer&#xD;
      may decrease lymphocyte T activity, resulting lowering effect of immune response.&#xD;
&#xD;
      This clinical trial will enroll 54 adults with newly diagnosed epithelial ovarian cancer&#xD;
      patients. Following receive of informed consent, they will randomly allocated to receive&#xD;
      whether vitamin D 2000 IU or placebo during chemotherapy period (6 cycles).&#xD;
&#xD;
      Subjects will fill out questionnaire on their first visit as well as each chemotherapy cycle&#xD;
      (each month). Questionnaire will ask about demographic data, meal intake, sun exposure, and&#xD;
      cachexia questionnaire (based on Cachexia Score). Subjects will also be examined on their&#xD;
      physical status, anthropometry (weight, height, waist circumference), as well as body&#xD;
      composition (fat mass, fat free mass, fat free mass index, phase angle).&#xD;
&#xD;
      Blood samples will be drawn from peripheral vein and sent to National Cancer Referral&#xD;
      Hospital laboratory to measure 25(OH)D level, interleukin-6, CD8 cytotoxic level, CD8&#xD;
      cytotoxic activity, and circulating tumor cells. Blood collection will be done on the first&#xD;
      visit, 3rd cycle of chemotherapy, and last cycle of chemotherapy. Subjects will be given&#xD;
      their samples result during follow-up visit.&#xD;
&#xD;
      Vitamin D3 (Prove D3Â®) is donated from PT. Kalbe Farma. Departement of Medicine Physic&#xD;
      Indonesia University as the third party which provides randomization and capsules containing&#xD;
      vitamin D and placebo. Randomization key will be opened by the third party after finishing&#xD;
      statistical data analysis. This study is being submitted a grant from Kalbe-BRIN.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 26, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention group: vitamin D 2000 IU ; Control group: placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Neither do investigator nor participants will not know the random allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of immune response in participants receiving vitamin D change from baseline as assessed by lymphocyte CD8</measure>
    <time_frame>6 months</time_frame>
    <description>lymphocyte CD8 is measured by flowcytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Find the change of vitamin D level</measure>
    <time_frame>6 month</time_frame>
    <description>vitamin D level is measured by Electro-Chemiluminescence Immunoassay (e CLIA). The normal range is 30-100 ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Find the daily intake of vitamin D from food</measure>
    <time_frame>1 month</time_frame>
    <description>The amount of vitamin D intake from food in one month is analyzed using food frequency questionnaire in microgram unit measurement. To find the daily intake from food is calculated the total intake in 1 month divided by 30 days. Recommended daily allowance of vitamin D intake from food is 15 microgram/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Find the rate of sun exposure</measure>
    <time_frame>1 week</time_frame>
    <description>sun exposure defined as total duration of sun exposure per day. It assessed using &quot;sun exposure questionnaire&quot;. It is calculated based on time outdoor multiply by amount of skin exposure (face, hand, arm, leg, sun bathing), added up everyday for one week. The minimum score is 0 and the maximum score is 56. No score is defined as either adequate or inadequate exposure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vitamin D in lowering inflammation</measure>
    <time_frame>6 months</time_frame>
    <description>defined inflammation as interleukin-6 which is measured by enzyme-linked immunosorbent assay in ng/ml unit measurement. Interleukin-6 increases if the level more than 4 pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vitamin D in lowering circulation tumor cells (CTC)</measure>
    <time_frame>6 months</time_frame>
    <description>the number of tumor cells in blood. Positive CTC if there are 5 tumor cells in 7,5 ml of blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of vitamin D in improving staging of cachexia</measure>
    <time_frame>6 month</time_frame>
    <description>a diagnostic tools for staging cachexia is measured by Cachexia Score (CASCO). The components of CASCO are body weight loss and composition, inflammation/metabolic disturbances, physical performance, anorexia, and quality of life. CASCO score is presented by numerical scale and classified as mild (score 0-25), moderate (26-50), severe (51-75), and terminal (76-100)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin D group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily vitamin D3 2000 IU on day 1 through day 180 Intervention: vitamin D3 2000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily placebo (saccharum lactis) on day 1 through day 180 Intervention: placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180</description>
    <arm_group_label>Vitamin D group</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-60 years old who are newly diagnosed with ovarian cancer based on&#xD;
             histopathology&#xD;
&#xD;
          2. epithelial ovarian cancer stage II-III&#xD;
&#xD;
          3. haven't received chemotherapy&#xD;
&#xD;
          4. pre-cachexia or cachexia&#xD;
&#xD;
          5. level of vitamin D below 30 ng/ml&#xD;
&#xD;
          6. no vitamin D allergy&#xD;
&#xD;
          7. ability and willingness to understand and provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. autoimmune disease&#xD;
&#xD;
          2. chronic liver disease&#xD;
&#xD;
          3. chronic renal disease&#xD;
&#xD;
          4. known had hypercalcemia&#xD;
&#xD;
          5. refractory cachexia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nurul Ratna Mutu Manikam, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indonesia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nurul Ratna Mutu Manikam, MD,MSc</last_name>
    <phone>62081210106679</phone>
    <email>nurul.ratna@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrijono Andrijono, Prof,MD,PhD</last_name>
    <phone>620816844824</phone>
    <email>andrijono@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>13430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Nurul Ratna Mutu Manikam, MD,MSc</last_name>
      <phone>62081210106679</phone>
      <email>nurul.ratna@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrijono Andrijono, MD,PhD,Prof</last_name>
      <phone>620816844824</phone>
      <phone_ext>Manikam</phone_ext>
      <email>nurul.ratna01@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nurul Ratna Mutu Manikam, MD,MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrijono Andrijono, MD,PhD,Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fiastuti Witjaksono, MD,MSc,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fariz Nurwidya, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sri Hartini, MD,MSc,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dharmais National Cancer Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>13430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Nurul Ratna Mutu Manikam, MD,MSc</last_name>
      <phone>62081210106679</phone>
      <email>nurul.ratna@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Sri Hartini Harijanto, MD,MSc,PhD</last_name>
      <phone>6208159005011</phone>
      <email>sri.harijanto@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>dr. Nurul Ratna Mutu Manikam, M.Gizi., Sp.GK</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Pre cachexia</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details will be provided at a later date</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

